PE20060402A1 - Combinacion farmaceutica de etinilestradiol y acetato de clormadinona - Google Patents

Combinacion farmaceutica de etinilestradiol y acetato de clormadinona

Info

Publication number
PE20060402A1
PE20060402A1 PE2005000595A PE2005000595A PE20060402A1 PE 20060402 A1 PE20060402 A1 PE 20060402A1 PE 2005000595 A PE2005000595 A PE 2005000595A PE 2005000595 A PE2005000595 A PE 2005000595A PE 20060402 A1 PE20060402 A1 PE 20060402A1
Authority
PE
Peru
Prior art keywords
ethinylestradiol
chlormadinone acetate
treatment
pharmaceutical combination
combination
Prior art date
Application number
PE2005000595A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Georg Schramm
Klaus-Michael Wilsmann
Janine Klose
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20060402A1 publication Critical patent/PE20060402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMBINACION DE ETINILESTRADIOL Y ACETATO DE CLORMADINONA, DONDE EL ETINILESTRADIOL SE ENCUENTRA EN UNA CANTIDAD DE 5 A 30 MICROGRAMOS Y EL ACETATO DE CLORMADINONA SE ENCUENTRA EN UN RANGO DE 1 A 5 MG. TAMBIEN ESTA REFERIDA A UN MEDICAMENTO QUE COMPRENDE AL MENOS 21 UNIDADES QUE CONTIENEN HORMONAS. DICHO MEDICAMENTO ES UTIL PARA EL TRATAMIENTO DE ALTERACIONES INDUCIDAS POR ANDROGENOS, PARA LA TERAPIA DE SUSTITUCION HORMONAL, PARA EL TRATAMIENTO DE DISMENORREA, PARA LA ESTABILIZACION DEL CICLO MENSTRUAL, PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DEL CICLO MENSTRUAL Y PARA LA CONTRACEPCION
PE2005000595A 2004-05-28 2005-05-27 Combinacion farmaceutica de etinilestradiol y acetato de clormadinona PE20060402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004026669A DE102004026669A1 (de) 2004-05-28 2004-05-28 Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
PE20060402A1 true PE20060402A1 (es) 2006-07-12

Family

ID=34982562

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000595A PE20060402A1 (es) 2004-05-28 2005-05-27 Combinacion farmaceutica de etinilestradiol y acetato de clormadinona

Country Status (11)

Country Link
US (1) US20050267081A1 (es)
EP (1) EP1753435A1 (es)
AR (1) AR049195A1 (es)
AU (1) AU2005247101B2 (es)
BR (1) BRPI0511864A (es)
DE (1) DE102004026669A1 (es)
EC (1) ECSP067030A (es)
MX (1) MXPA06013800A (es)
PE (1) PE20060402A1 (es)
RU (1) RU2394579C2 (es)
WO (1) WO2005115402A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006062119A1 (de) * 2006-12-22 2008-06-26 Grünenthal GmbH Arzneimittel zur Behandlung von Hauterkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
AU4805085A (en) * 1984-09-05 1986-03-24 Schering Aktiengesellschaft Mittel zur behandlung von androgenisierungserscheinungen und verwendung von antiandrogenen zur herstellung des mittels
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
EP1071428A2 (en) * 1998-04-17 2001-01-31 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
CN101099734A (zh) * 2002-08-15 2008-01-09 惠氏公司 用于治疗体温调节机能障碍的5HT2a受体的激动作用
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE

Also Published As

Publication number Publication date
MXPA06013800A (es) 2007-02-02
AR049195A1 (es) 2006-07-05
DE102004026669A1 (de) 2005-12-15
AU2005247101B2 (en) 2011-02-17
EP1753435A1 (de) 2007-02-21
BRPI0511864A (pt) 2008-01-22
US20050267081A1 (en) 2005-12-01
ECSP067030A (es) 2006-12-29
RU2006145077A (ru) 2008-07-10
RU2394579C2 (ru) 2010-07-20
AU2005247101A1 (en) 2005-12-08
WO2005115402A1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
US10744143B2 (en) Therapeutic and method of use
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
AR048106A1 (es) Dispositivo de distribucion de drogas visible por rayos x
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
HRP20161380T1 (hr) Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
HUP0301813A2 (hu) Nem-orális androgén szteroidok
PE20060368A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
BRPI0510034A (pt) forma de dosagem para distribuição de múltiplas formas de fármacos
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
PE20060402A1 (es) Combinacion farmaceutica de etinilestradiol y acetato de clormadinona
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
JP2002540148A5 (es)
DE502006000771D1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
BRPI0417530B8 (pt) composição para a liberação transdérmica de hormônios sem a necessidade de melhoradores de penetração, sistema terapêutico transdérmico, e kit
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
ES2608816T3 (es) Composición farmacéutica oral de desmopresina
JP2006508071A5 (es)
AR063712A1 (es) Tratamiento del dolor usando satraplatino

Legal Events

Date Code Title Description
FC Refusal